Enhancing the antitumor efficacy using a combination of FGFR4 Inhibitor (H3B-6527) and oxaliplatin in gastric cancer. - Bhat N; Soutto M; Chen Z; Al-Mathkour M; Silvia Giordano; Chwihne M; Genoula M; Ballout F; Zhu S; McDonald OG; El-Rifai W (Neoplasia (New York, N.Y.), 2026)